A CRISPR-Cas9 platform for primary human hepatocytes enables arrayed screening and in vivo validation of HBV host factors
Ansgar F. Stenzel, Antonis Athanasiadis, Georgios Dangas…·Eleftherios Michailidis
The paper develops CRISPR-Cas9 delivery methods for primary human hepatocytes to enable efficient gene editing and screening of HBV host factors.